Weimin Wang

Company: SanegeneBio

Job title: Chief Executive Officer

Seminars:

Unlocking the Full Potential of RNAi with LEADTM (Ligand & Enhancer Assisted Delivery) 11:30 am

Delivery is the biggest hurdle to harnessing RNAi potential as a new drug modality GalNAc conjugate technologies have revolutionized RNAi for liver targets. Extrahepatic delivery is the new frontier for RNA Sanegene’s LEAD™ technology focusing on conjugate approach effectively delivers RNAi to specific tissues or cells of therapeutic relevanceRead more

day: Day 2